Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05666479 · ClinicalTrials.gov registry record
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
A clinical trial of Diabetes Mellitus, Type 2 and Arthroplasty, Replacement, Knee, sponsored by Stony Brook University.
- Active
- Registry status
- 32
- Enrollment target
- 1
- Study location
NCT05666479: Active study of Diabetes Mellitus, Type 2 and Arthroplasty, Replacement, Knee, sponsored by Stony Brook University.
NCT05666479 is a study of Diabetes Mellitus, Type 2 and Arthroplasty, Replacement, Knee that is active but no longer recruiting, run by Stony Brook University. The registered enrollment target is 32 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05666479, a study of Diabetes Mellitus, Type 2 and Arthroplasty, Replacement, Knee, is active but no longer recruiting, sponsored by Stony Brook University.
- ACTIVE NOT RECRUITING
- Registry status
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to analyze the efficacy and accuracy of real-time continuous glucose monitoring devices (rtCGM) in patients with Type 2 diabetes undergoing inpatient elective hip or knee surgery in the pre-, peri-, and post-operative setting at Stony Brook University Hospital (SBUH).
Conditions Studied
Interventions
- DEVICE Dexcom G6 Pro Continuous Glucose Monitor (CGM)
Study Locations (1)
New York
- Stony Brook University - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-09-09 |
| Est. Completion | 2024-09 |
What the registry record for NCT05666479 still lists
NCT05666479 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Dexcom G6 Pro Continuous Glucose Monitor (CGM) is the first listed.
NCT05666479 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05666479 about?
NCT05666479 is a clinical study titled "CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery". The purpose of this study is to analyze the efficacy and accuracy of real-time continuous glucose monitoring devices (rtCGM) in patients with Type 2 diabetes undergoing inpatient elective hip or knee surgery in the pre-, peri-, and post-operative setting at Stony Brook University Hospital (SBUH).
What is the current status of trial NCT05666479?
This trial is currently active not recruiting. The enrollment target is 32 participants. The study started on 2022-09-09. Estimated completion is 2024-09.
What conditions does trial NCT05666479 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Arthroplasty, Replacement, Knee, Arthroplasty, Replacement, Hip.
What interventions are being tested in trial NCT05666479?
The interventions under investigation include: Dexcom G6 Pro Continuous Glucose Monitor (CGM) (DEVICE).
Who is sponsoring clinical trial NCT05666479?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05666479 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05666479's enrollment target sits among peer trials
32 293rd of 348 higher than 55 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI